Dec. 5, 2019: The value of pre-treatment drug resistance testing; resistance rates among viremic Americans; persistent pneumonia incidence among people with HIV; mixed HIV prevention results for the U.S. National HIV Strategy.
Re-entry planning can help prevent opioid overdose and enable people living with HIV to connect with and stay in care.
Will a given development in HIV make a difference in the clinic? Will it change practice? Is this something I should know if I take care of people living with HIV? The answer to each of these must be yes for the story to make the list.
Whether lamivudine/dolutegravir is sufficient to achieve and maintain viral suppression was last year's question. As we move to 2020, a new question could be asked: Are three-drug regimens still necessary?
The likely launch of injectable cabotegravir/rilpivirine in early 2020 will be interesting, writes David Wohl, M.D. One big question: How smoothly will the rollout go?
The findings will help providers manage patients who have known or potential resistance to NRTIs, but who we want to place on a simplified antiretroviral regimen.
Transgender people face discrimination in many facets of life. When it comes to discrimination in clinical settings, it can affect their health for the worse.
Nov. 20, 2019: Adherence required to maintain suppression; the accuracy of Framingham scores in assessing cardiovascular risk; long-term success rates for kidney transplants; integration of hypertension services with HIV care.
A systematic review of research between 2000 and 2016 found no studies of interventions specifically designed to support medication adherence among HIV-positive black women.
Taking more than five medications could be a problem. And many people with HIV are at risk of being on medication overload.